Guizhou Yibai Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2023: USD 53.19 M

Guizhou Yibai Pharmaceutical Co., Ltd. Operating Cash Flow is USD 53.19 M for the year ending December 31, 2023, a 6.29% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Guizhou Yibai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD 50.04 M, a -65.97% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD 147.03 M, a 161.74% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD 56.17 M, a 7.85% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Operating Cash Flow for the year ending December 31, 2019 was USD 52.09 M, a 67.16% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shanghai Stock Exchange: 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd.

CEO	Ms. Ya Qi Dou
IPO Date	March 23, 2004
Location	China
Headquarters	No. 220-1, Baiyun Avenue
Employees	5,509
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years